Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vargatef

- PMLiVE

PD-1 cancer market overrated, says new report

The immuno-oncology market for new oncology drugs may be worth half of current expectations

- PMLiVE

Bowel Cancer UK launches research initiative

Announcement for its R&D commitment comes during Bowel Cancer Awareness Month

EISAI

Eisai’s thyroid cancer drug Lenvima nears EU approval

Positive recommendation by the CHMP could see the orphan drug used in Europe within three months

- PMLiVE

WHO: Medicine costs ‘too high’ for European governments

New report shows transparency and co-operation needed to help reduce drug prices

- PMLiVE

Final NICE ‘no’ for Celgene’s Imnovid

England’s pricing watchdog says multiple myeloma drug is just too expensive for the NHS

- PMLiVE

Merck’s Keytruda beats BMS’ Yervoy in melanoma face-off

Both firms competing for a leading share in the highly competitive skin cancer drug market

- PMLiVE

Cancer charity partners with research council for innovation

CRUK teams up with multi-disciplinary groups to help develop new oncology products

- PMLiVE

Lilly/Boehringer’s diabetes combination Glyxambi debuts in US

Companieslaunch first fixed-dose of empagliflozin and linagliptin

- PMLiVE

Takeda spends $230m on oncology biotech deal

Buys into ImmunoGen’s antibody-drug conjugate technology

- PMLiVE

Merck KGaA supports Get Tested colorectal cancer campaign

Coincides with the first World Metastatic Colorectal Cancer Day

- PMLiVE

Boehringer to move psoriasis programme into phase III

Candidate outperformed J&J’s rival Stelara 

Eli Lilly HQ

Lilly signs cancer pact with Chinese biotech

Marks first major deal between a Western pharma company and a Chinese biotech

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links